Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb:27 Suppl 3:21-27.
doi: 10.1111/hae.14035. Epub 2020 May 29.

Redefining prophylaxis in the modern era

Johnny N Mahlangu  1 , Victor Blanchette  2 , Robert Klamroth  3
Affiliations

Redefining prophylaxis in the modern era

Johnny N Mahlangu et al. Haemophilia. 2021 Feb.

Abstract

Prophylaxis is the globally accepted standard of care for persons with haemophilia and presents many advantages over episodic treatment. The prophylaxis benefits include bleed reduction, reduction in musculoskeletal complications and improvement in the quality of life. The currently evolving novel therapies for the management of haemophilia has ushered a new era characterized by improved prophylaxis targets and outcomes. These redefined targets and outcomes have necessitated the need to also redefine prophylaxis. In this state-of-the-art review, we redefine prophylaxis in the modern era by revisiting its definition, presenting data to support higher trough levels to achieve with prophylaxis and introducing steady-state haemostasis as a possible new target for prophylaxis.

Keywords: modern era; novel therapies; prophylaxis; redefinition; steady-state; trough levels.

PubMed Disclaimer

References

REFERENCES

    1. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535-544.
    1. Young G, Liesner RI, Chang T, et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019;134(24):2127-2138.
    1. Weyand AC, Dorfman AL, Shavit JA, et al. Emicizumab prophylaxis to facilitate anticoagulant therapy for the management of intra-atrial thrombosis in severe haemophilia with an inhibitor. Haemophilia. 2019;25(3):e203-e205.
    1. Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379(9):811-822.
    1. Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(9):809-818.

LinkOut - more resources